

# Glioblastoma

[View the current Glioblastoma InDepth page on BioPortfolio.com \(PDF\)](#)  
(<http://www.bioportfolio.com/indepth/Glioblastoma.html>) - Regularly Updated.

## Recent Publications on Glioblastoma:



- [Control of the G2/M checkpoints after exposure to low doses of ionising radiation: Implications for hyper-radiosensitivity.](#)  
*Two molecularly distinct G2/M cell cycle arrests are induced after...* 21st November, 2009  
Institut Curie, Centre de Recherche, Bat. 110-112, Centre universitaire,- DNA Repair (Amst). 2009 Nov 17. ([DOI Direct Link](#))
- [Two-Step Synthesis of Multivalent Cancer-Targeting Constructs.](#)  
*Selective targeting of constructs to pathological cells by conjugating one...* 21st November, 2009  
School of Biological and Health Systems Engineering, Center for- Biomacromolecules. 2009 Nov 19. ([DOI Direct Link](#))
- [CXCL12/CXCR4 promotes motility and proliferation of glioma cells.](#)  
*Glioblastoma (GBM) is the most aggressive and malignant brain tumor....* 20th November, 2009  
Centre for Neuroscience and Cell Biology and CIMAGO, University of- Cancer Biol Ther. 2010 Jan 17;9(1).
- [Treatment of glioblastoma multiforme cells with temozolomide-BioShuttle ligated by the inverse Diels-Alder ligation chemistry.](#)  
*Recurrent glioblastoma multiforme (GBM), insensitive against most...* 19th November, 2009  
German Cancer Research Center, Dept of Imaging and Radiooncology,- Drug Des Devel Ther. 2009 Feb 6;2:289-301.
- [Induction of cytotoxicity, apoptosis and cell cycle arrest by 1-t-butyl carbamoyl, 7-methyl-indole-3-ethyl isothiocyanate \(NB7M\) in nervous system cancer cells.](#)  
*Our group has recently developed 1-(t)butyl carbamoyl,...* 19th November, 2009  
Molecular Therapeutics Laboratory, Program in Women's Oncology, Department- Drug Des Devel Ther. 2009 Feb 6;2:61-69.
- [Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study.](#)  
*Background: We evaluated bevacizumab with metronomic etoposide among...* 19th November, 2009  
[1] Department of Surgery, The Preston Robert Tisch Brain Tumor Center,- Br J Cancer. 2009 Nov 17. ([DOI Direct Link](#))
- [Glioblastoma Proto-oncogene SEC61 \$\gamma\$  Is Required for Tumor Cell Survival and Response to Endoplasmic Reticulum Stress.](#)  
*Glioblastoma multiforme is the most prevalent type of adult brain tumor...* 19th November, 2009  
Department of Pathology, The Pediatric Brain Tumor Foundation Institute,- Cancer Res. 2009 Nov 17. ([DOI Direct Link](#))

- [Hypoxia Protects Neuronal Cells from Human Prion Protein fragment-induced Apoptosis.](#)  
*Prion diseases are neurodegenerative disorders characterized by the...*19th November, 2009  
Center for Healthcare Technology Development, Korea Zoonoses Research- J Neurochem. 2009 Nov 16. ([DOI Direct Link](#))
- [Bevacizumab for recurrent ependymoma.](#)  
*BACKGROUND: Ependymoma is a rare type of glioma, representing 5% of all...*18th November, 2009  
Department of Neurology, Kaiser Permanente, Los Angeles Medical Center,- Neurology. 2009 Nov 17;73(20):1677-80. ([DOI Direct Link](#))
- [Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations.](#)  
*BACKGROUND: Glioblastoma multiforme (GBM) is an umbrella designation that...*17th November, 2009  
Department of Neurosurgery, Memorial Sloan Kettering Cancer Center, New- PLoS One. 2009 Nov 13;4(11):e7752. ([DOI Direct Link](#))
- [Suppression of cellular proliferation and invasion by the concerted lipid and protein phosphatase activities of PTEN.](#)  
*PTEN is a tumour suppressor with phosphatase activity in vitro against...*17th November, 2009  
Division of Molecular Physiology, College of Life Sciences, University of- Oncogene. 2009 Nov 16. ([DOI Direct Link](#))
- [Activity and cellular localization of an oncogenic glioblastoma multiforme-associated EGF receptor mutant possessing a duplicated kinase domain.](#)  
*A mutation of the epidermal growth factor receptor (EGFR) that results in...*17th November, 2009  
Department of Biomolecular Chemistry, University of Wisconsin, Madison,- Oncogene. 2009 Nov 16. ([DOI Direct Link](#))
- [Isocitrate Dehydrogenase Mutations Are Rare in Pheochromocytomas and Paragangliomas.](#)  
*Context: Paragangliomas and pheochromocytomas are neuroendocrine tumors...*17th November, 2009  
Department of Pathology (J.G., E.K., R.R.d.K., W.N.M.D.), Josephine- J Clin Endocrinol Metab. 2009 Nov 13. ([DOI Direct Link](#))
- [Isolation of cancer stem-like cells from a side population of a human glioblastoma cell line, SK-MG-1.](#)  
*Accumulating evidence suggests that in several types of brain tumors,...*17th November, 2009  
Department of Neurosurgery, Keio University School of Medicine, Tokyo,- Cancer Lett. 2009 Nov 12. ([DOI Direct Link](#))
- [A study on partially biodegradable microparticles as carriers of active glycolipids.](#)  
*This paper describes a study on the preparation and characterisation of...*17th November, 2009  
Institute of Polymer Science and Technology, CSIC. CIBER-BBN. C/ Juan de- Acta Biomater. 2009 Nov 10. ([DOI Direct Link](#))

## BioNews Results for Glioblastoma

- [Paloma Pharmaceuticals Presents at the AACR-NCI-EORTC International Conference Molecular Targets and Cancer Th](#)  
*Pharma Live: Nov 21 2009 2:54AM Matching: glioblastoma*
- [Questions and answers on the recommendation for the refusal of a change to the marketing authorisation for Ava](#)  
*Pharma Live: Nov 20 2009 5:11PM Matching: glioblastoma*
- [European advisory committee declines to recommend Avastin approval for deadly brain cancer](#)  
*Drug Store News: Nov 20 2009 7:39PM Matching: glioblastoma*
- [Committee For Medicinal Products For Human Use Summary Of Positive Opinion For Temozolomide Teva](#)  
*Pharma Live: Nov 20 2009 5:10PM Matching: glioblastoma*

- [Committee For Medicinal Products For Human Use Summary Of Positive Opinion For Temomedac](#)  
*Pharma Live: Nov 20 2009 5:10PM Matching: glioblastoma*
- [European Medical Advisory Committee Does Not Recommend Approval Of Avastin For Deadly Form Of Brain Cancer](#)  
*Pharma Live: Nov 20 2009 5:11PM Matching: glioblastoma*
- [European medical advisory committee does not recommend approval of Avastin for deadly form of brain cancer](#)  
*WebWire: Nov 20 2009 4:24PM Matching: glioblastoma*
- [EU Panel: Affirm Benefits Of Celvapan, Focetria, Pandemrix](#)  
*Lloyd's: Nov 20 2009 3:08PM Matching: glioblastoma*
- [EU Panel: Affirm Benefits Of Celvapan, Focetria, Pandemrix](#)  
*Morningstar.com: Nov 20 2009 1:55PM Matching: glioblastoma*
- [BRIEF-EU agency rejects use of Roche's Avastin in glioblastoma](#)  
*Interactive Investor International: Nov 20 2009 1:44PM Matching: glioblastoma*
- [EU Panel: Affirm Benefits Of Celvapan, Focetria, Pandemrix](#)  
*CNN Money: Nov 20 2009 1:41PM Matching: glioblastoma*
- [EU Panel: Affirm Benefits Of Celvapan, Focet](#)  
*Hemscott: Nov 20 2009 1:41PM Matching: glioblastoma*
- [BRIEF-EU agency rejects use of Roche's Avastin in glioblastoma](#)  
*Forbes.com: Nov 20 2009 1:38PM Matching: glioblastoma*
- [BRIEF-EU agency rejects use of Roche's Avastin in glioblastoma](#)  
*FinanzNachrichten.de: Nov 20 2009 1:26PM Matching: glioblastoma*
- [EU Panel Backs Elonva from N.V. Organon](#)  
*Hemscott: Nov 20 2009 1:23PM Matching: glioblastoma*

## Glioblastoma Patents:



- 7605266- [Azaindole inhibitors of Aurora kinases](#)
- 7608739- [Mitotic kinesin inhibitors](#)
- 7609061- [Demagnetized implant for magnetic resonance imaging](#)
- 7611692- [Gastrin releasing peptide compounds](#)
- 7611704- [Compositions and methods for treating viral infections using antibodies and immunoconjugates to aminophospholipids](#)
- 7611711- [VEGFR-3 inhibitor materials and methods](#)
- 7611854- [Yeast cells engineered to produce pheromone system protein surrogates, and uses therefor](#)
- 7611865- [Polynucleotides encoding truncated glial cell line-derived neurotrophic factor](#)
- 7611879- [27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 and 65577 molecules and uses therefor](#)
- 7611893- [Metal-binding therapeutic peptides](#)
- 7612039- [Method of cell growth inhibition with agnoprotein](#)
- 7608643- [Compounds for inhibiting KSP kinesin activity](#)
- 7608635- [Pyrazole compounds that modulate HSP90 activity](#)
- 7608634- [Substituted pyrrolines as kinase inhibitors](#)
- 7608255- [Replication-competent anti-cancer vectors](#)

- 7608257- [Sensitization of chemotherapeutic agent resistant neoplastic cells with a virus](#)
- 7608259- [Methods of cancer diagnosis and therapy targeted against a cancer stem line](#)
- 7608260- [Stabilized immunoglobulins](#)
- 7608264- [Antibodies that bind to pleiotrophin growth factor receptor](#)
- 7608267- [Multifunctional cytokines](#)
- 7608269- [Compositions and methods for treating cancer by modulating HER-2 and EGF receptors](#)
- 7608394- [Methods and compositions for phenotype identification based on nucleic acid methylation](#)
- 7608429- [Methods and compositions for increasing antibody production](#)
- 7608612- [Radiosensitizer formulations and methods for use](#)
- 7612092- [Nitrogen-containing aromatic derivatives](#)
- 7612162- [Peptide analogs capable of enhancing stimulation of a glioma-specific CTL response](#)
- 7618631- [Treatment with anti-ErbB2 antibodies and EGFR-targeted drugs](#)
- 7618633- [Antibodies that bind CD40 and methods of treating cancer and enhancing immune responses](#)
- 7618637- [Heat shock protein-based vaccines and immunotherapies](#)
- 7618816- [Metal-binding therapeutic peptides](#)
- 7618936- [Methods for treating and diagnosing cancer with WNT inhibitory Factor-1 \(WIF-1\)](#)
- 7618939- [Compositions and methods to prevent cancer with cupredoxins](#)
- 7618947- [Modulation of HIF-1 beta expression](#)
- 7618971- [Mitotic kinesin inhibitors](#)
- 7618981- [Imidazopyridinyl-benzamide anti-cancer agents](#)
- 7619006- [Conjugated psychotropic drugs and uses thereof](#)
- 7618626- [Combination treatment for non-hematologic malignancies](#)
- 7618622- [Treatment of Parkinson's disease and related disorders using postpartum derived cells](#)
- 7615632- [Crystalline forms of temozolomide](#)
- 7612178- [Anti-IGF-1R antibodies and uses thereof](#)
- 7612182- [Anti-IL-6 antibodies, compositions, methods and uses](#)
- 7612202- [Process for preparing temozolomide](#)
- 7615209- [Compositions of NDV and methods of use thereof for treatment of cancer](#)
- 7615213- [Antibodies against human interleukin-13 and pharmaceutical compositions thereof](#)
- 7615214- [Anti-human VEGF receptor Flt-1 monoclonal antibody](#)
- 7615215- [Anti-human VEGF receptor Flt-1 monoclonal antibody](#)
- 7615223- [Selected immunoconjugates for binding to aminophospholipids](#)
- 7615353- [Tivozanib response prediction](#)
- 7615529- [Methods and compositions for modulating hyperstabilized c-met](#)
- 7619068- [Ovr110 antibody compositions and methods of use](#)

\*\*\*

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road,

